Search Technologies
Displaying 201 - 210 of 226 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Vaccine for Prevention of Sepsis and Broad Protection Against Gram-Negative Bacterial Infections
Published Wednesday, May 28, 2014The “J5dLPS/OMP” vaccine, created by academic and federal research collaborators led by Prof. Alan Cross, is a clinical-stage vaccine for the prevention of sepsis and protection against infection by a wide variety of Gram-negative bacteria. The vaccine comprises detoxified core lipopolysaccharide from Escherichia coli J5 complexed with...
Investigator(s): Alan Cross, Apurba Bhattacherjee, Wendell Zollinger, Steven Opal
Categories: Vaccine
Keyword(s): vaccine, gram-negative infection, sepsis prevention
Docket: AC-2006-005
-
Injectable Matrix for Load-Bearing Bone Repair
Published Wednesday, May 28, 2014Dr. Huakun Xu and his team at UMB have created an injectable and mechanically strong construct to be used with or without stem cells for bone tissue engineering. The UMB inventors have designed a strong, moldable, and injectable stem cell-containing scaffold for bone tissue engineering that can be used in...
Investigator(s): Huakun Xu, Michael Weir
Categories: Bioengineering, Dental
Keyword(s): bone repair, dental
Docket: HX-2010-041 & HX-2012-027
-
Inhibitors of S100 Proteins for the Treatment of Cancer and Other Diseases Involving Uncontrolled Cell Growth via an S100-Dependent Pathway
Published Wednesday, May 28, 2014Small molecules have been identified, using rational drug design, that bind to a site on S100 proteins, rendering S100 incapable of inactivating p53 tumor suppressor protein. Inhibitors of S100 thus restore tumor suppressor activity of the p53 protein by inhibiting the S100-p53 interaction. Inhibitors are specific to different members of the...
Investigator(s): David Weber, Joseph Markowitz, France Carrier
Categories: Diagnostics, Therapeutics, Small molecules
Keyword(s): tumor, cancer, S100 proteins, research tools
Docket: DW-2002-041
-
Inhibitors of Extracellular Signal-Regulated Kinase (ERK) regulated signaling pathways
Published Wednesday, May 28, 2014This technology is a set of novel ATP-independent, extracellular signal-regulated kinase (ERK) inhibitors that have the potenital to provide specific targeting compared to existing ERK1/2 inhibitors. The lead ATP-independent ERK inhibitor candidates, interact with specific ERK substrate...
Investigator(s): Paul Shapiro, Stephen Fletcher, Alex MacKerell
Categories: Therapeutics, Small molecules
Keyword(s): Signal-Regulated Kinase, ERK
Docket: PS-2013-025,PS-2013-054
-
Inhibitors of Cell Migration and Shape Changes by Inhibiting Cortactin and HS-1 Mediated Actin Polymerization
Published Wednesday, May 28, 2014The present invention is a novel approach to suppress metastasis by targeting cortactin (or HS-1), an actin -associated protein. Cortactin is overexpressed in breast cancer and head and neck carcinomas where it plays a major role in tumor progression by promoting metastasis. Preventing binding of cortactin (or HS-1) to Arp2/3 blocks actin...
Investigator(s): Xi Zhan, Takehito Uruno
Categories: Therapeutics, Small molecules
Keyword(s): neck carcinomas, head carcinomas, cancer
Docket: XZ-2005-108
-
TLR Inhibitors for Treatment of Influenza, Cancer, Allergy, Inflammation and Prevention of Endotoxic Shock
Published Wednesday, May 28, 2014The Toll-like receptors (TLRs) play a vital role in eradicating pathogenic microbial infections, eliminating necrotic host cells and enhancing tissue repair in the host. On the flip side, chronic TLR activation leads to inflammatory disease and “systemic” activation of TLRs may lead to death. ...
Investigator(s): Vladimir Toshchakov
Categories: Research Tools, Antibodies, & Reagents, Platforms, Therapeutics, Biologics
Keyword(s): TLR, decoy peptides, inflammation, cancer, microbial infections, immune disorders, allergy, endotoxic shock, TRAM, TRIF, TIRAP and MyD88
Docket: VT-2012-029 VT-2012-052
-
Inhibition of Breast Cancer Metastases using Natural Extracts from Colocasia Esculenta (Taro).
Published Wednesday, May 28, 2014Studies link breast cancer, the second leading cause of cancer-related mortality in US women, with the occurrence of metastatic disease and spread. However, the majority of current therapies focus on the treatment of solid tumors with very little focus on targeting the metastatic process. Due to the significant correlation of secondary tumors...
Investigator(s): Namita Kundu, Amy Fulton
Categories: Therapeutics, Biologics, Natural Compounds
Keyword(s): breast cancer, cancer
Docket: NK-2009-001
-
Inhibition Of Metastatic Tumors
Published Wednesday, May 28, 2014Cancer is the second-leading cause of death in the United States. Death of cancer patients is most often caused by metastatic spread of tumor cells from the primary tumor site through the bloodstream where the cells lie dormant for long periods. These dormant cells will invade secondary sites such as the lung, liver or kidney where they develop...
Investigator(s): Stuart Martin, Rebecca Whipple, Agnes Cheung
Categories: Devices, Imaging devices, Software + Algorithm, Healthcare, Education/Training/Multimedia
Docket: SM-2006-059
-
IL-25 treatment of obesity and metabolic disorders
Published Tuesday, May 27, 2014Obesity is associated with chronic low grade inflammation in adipose tissues, mainly due to the accumulated immune cells (Th1/Th17 cells, macrophages etc.) that release pro inflammatory cytokines into the system. These cytokines contribute to development of the “metabolic syndrome.” IL-25 is an important regulator in the...
Investigator(s): Aiping M. Zhao, Terez Shea-Donohue
Categories: Therapeutics, Biologics
Keyword(s): IL-25, Biologic, Therapeutic
Docket: AZ-2011-020
-
High affinity recombinant sea lamprey antibodies selected by a yeast surface display platform.
Published Tuesday, May 27, 2014Immunoglobulin-based antibody therapeutics are enjoying unprecedented success. Hundreds are in clinical trials, with revenues from the top five (Rituxan, Remicade, Herceptin, Humira, and Avastin) increasing from $6.4 billion in 2004 to $11.7 billion in 2006 (Dimitrov & Marks, 2009). Thousands more are available for biological detection...
Investigator(s): Zeev Pancer, Roy Mariuzza, Satoshi Tasumi, Carlos Velikousky
Categories: Diagnostics, Platforms
Docket: ZP-2010-085